


ARTICLE INFO

ABSTRACT

Article history: 1-o | - | Keywords: ß 6 -

fl -)) 0 d fi (6 -) -1 fi -1 -1 0_fi o 0 0 o fi fi -γ--10--γ -10, 0 0 1 d I

1. Introduction



6 6 -0 0 0 , 0 00. 0 0 0 6 6 -0 <u>6</u> 6 --1 . -1 0 0 0 1 1 0 φ 6 6 0 oL . 1 б⁶ - б ras o^l o^l 0 0- 0 0 + 1 0 0 0 6 0 0 0 0 0 Ь. 0

2. Materials and methods

2.1. Vaccine formulations

16 6 -0,0,0,(--) 0 0 o o Escherichia coli o o d _ fi 0 0 0 0 0 %. o o o c 0- 6- 00 0 0 0

2.2. Tumor cell line


2.3. Tumor model and vaccination

2.4. CTL assay

- 16 0 0 (10) 10%- , 00 / 0 0 0 0 0 fi 0.0 000 - % 06 (0 µ/) 6 -)), | . 0 o_ _ _ | (¹). O^l 0 0 0 0) 0 6 0 0 0

2.5. Elispot assay of IFN- γ - and IL-10-secreting cells

2.6. Flow cytometry for Treg cells



600 0 0 0 00 g 0 10 0-100% - 0 -00 d 0 - fi 0 100%- 0 -._ 0 07 0 0) f]0 d 0 0 0 (o 0 0 0 0 (1 10) 0 0 (¹ µ) 0 0 0 0 0 0 0 (μ) (0 0) 0 o | 0 fi) 0 0 0 0 0 b 100 μ 0 1 (- 0) 0 0 κ ο (_O 0 0 0 (). 0 0 0 fi 0 0 0 0 6 0 1 0μ [|] 11 0 flo

2.7. IgG and isotypes

fi 0 fi 0 100 $1 \mu /$ 6,0 0 0.01 - 0 0 0 - 0 (/) (1) 0.0 % %-. 0 0 1 . 1 100 0 100μ0 ļ 0 0 0 0 1' 0. - 01. - o (1' 000) , 100μο ο .,)] 0 00 , 100μο - 01. 1_ ο ο 100μ/ο 0 0 (, ', , -- 0 , 0 .0) () 0.1 -1 10 1 0 ο ο 0¹μο 0 0 d 0 (0 -0 0 0 0). (.1) 0 0 0 0 0 0 1, 1 0 100 µ 0 [|] - 0 0 0 0 00, (1 1000) () 0 I .


2.8. mRNA expression of IL-10, VEGF, STAT3 and IFN- γ in tumors

0 0 1 4 0 0 0 0 0 0., 1 (00 1). ||'|

Table 1

0 - **.**

	and the second second
-10	_0
γ	_0
-	_0
, -	_0
β-	-0



2.9. Statistical analysis

t-1 'l 0,0 0 0 b 0 1. 0 --1 o , 1 lo fi o | 0 - 0 0 -0 0 fill $P \le 0.0$. 0

3. Results

3.1. Docetaxel and HPV-LFP synergistically suppress tumor growth

(-6) -1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0), (_ 0 0 0 fi 0 0 0 (P < 0.0). 1_ 0 0 0 0 0 0 06.% 0 . %, . % 0 10μ (P < 0.0). 0 . 00 μ 0 o fi (P < 0.0). 0 0

3.2. Docetaxel and HPV-LFP synergistically increase the survival of mice inoculated with TC-1 cells

(-6) 0 0 0 0 -1-.- b 0 1 -1 0 0 0 060 0 0 0 0 0 1 o b. . 0 01 %0 0 0.0 60 0 $0 \quad 0\%^{i} (P < 0.0)$.

3.3. Docetaxel and HPV-LFP synergistically activate CTL cells

(-6) 0 0 0 1 0 ο. 0 0 0 fi 0 00 1.1 0 -00 0 0 0 b 0 -1 . 00 00 00 - -0 0 fi 0 1 6






 Fig. 2. 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0
 0





-6 / _0) - .1. 0 00 1. -1) 0 6 0 Fig. 4. (0 0 (0 1 11 I 6 -۱_ 0 0 0 (1Ō) (10 µ /) 0 /--'| 0 0 0 (/)⁰ 01, 01, 101 0 ۰1, fi 0 0 0 . 0 I 1 I 1 11 0 $P \le 0.0^{\circ}$ I I 11 $P \leq 0.01$, 0




Fig. 5. - γ ο -γ) ο -10) 0 (0 _ . 1. / 00,000). (0 P ο 1. ο -γ()ο -10 (-6 / 0) 6 % fi (o - - - y) o -10) 0 (0 -10() 0 0 . . (≤ 0.0 1 I 111

3.4. Docetaxel and HPV-LFP synergistically increase IFN- γ and decrease IL-10 secreting cells

3.5. Docetaxel enhances HPV-LFP-elicited antibody responses

3.6. Docetaxel decreases Treg cells in CD4⁺ splenocytes

-6) (+ O 0 0 -1 fi d -1-10 I 00 μ fi (P - 0.00)00 μ 0.00) (P

3.7. Docetaxel decreases Treg cells in tumors

3.8. Docetaxel and HPV-LFP synergistically up-regulate IFN- γ and down-regulate IL-10, VEGF and STAT-3 mRNA expression in tumors

μ -10 0 0 fi 1-10, $-\gamma$ b fi -10.

4. Discussion

fi) 0 -1 fi ĥ [|] fi -10-n (b o d 1. d 11.





Fig. 6. (-6 / 0) 0 _ .1. () . -1 0 . . P ≤ 0.0 (). fi



0 flo 0 -6 / 0) Fig. 7. (0 . 1. 0 0 0 0 1 0 1 0 0 -_0 0 +_0 10 0 0 , -), d (0 fi 0 0 0)/ 0 (--01)- 0 0 1 0 0 0 fi 0 0 . , ()-(0 1 0 0 0 0 (%) 0 . .P 0 . , 1 1 1 0 0 t-0

1

0 0 , 6 ß L 0 6 1 1 1 0 0 0 6 -6, 0 fi 0 10 0 0 0 0 0- 0 0 0 _ 0 0 0 0 0 fi -0 -7 0 0 00 0 6 /fi -I 0 00 ,6 0 00 0 0 0 (0 6 6 0 0 1) 0 0 -1. Ο, fi 0 0 0 1 1 1

0 0 fi 0 0 0 .

d 0 0 0 %) fi (0 0 0 . % 6 %, 0 1) (-.). 0-0 fi 0 0 1). -1 (_ 0 1 0

ο ο ο ο - ο - ο ο ο 00 μ ο ο ο 00 μ ο ,





Fig. 8. flo .1. -1 0 0 0 0 0 0 0 - fi 0 0 6ol -fi 0 0 100%_ 0 -1 +)- ¹0 (_0 _0 (o o (%) fi o | _ . P I

b .6 b 0 0 I .6 fi _ . 1 1 fl I 1. , I fl 1 1



ο ο -10, - -γ, 0 .--Fig. 9. _ () 0 . 1. -1 I 000. 0 0 -10, - -γ, fi . 0 (β-) fi o . .P . β-I - _

0μ 0 00μ. , 00μo 100, 00 0 00 µ 0 0 0 fi l 0 0 fi I Ь Ь , 0.

1. fi d . fi L L 0-1/0 d fi fi $-\gamma - 1$ +- -

0-(b L 0 0) fi I , I l 0 0 I

0 -10 0 0 o 1 0. 0 -10 0 1 -10 0 0 0 0 0 0 0 0 0 0 0 -10 0 . 0 0 0 0 fi -10-0 0 0 0 0 . (-).

00 0 0 o | 0 0 0 0 0 0 0 0 6 -10 $-\gamma$ 0 +0 0 fi 0 0 0 0 0 0 0 0 0. - -γ, d 0 -10. 0 1 0 0 -0

0, o 0 1 ol 0 11 0 6 0 0 6 0 10 0 o 1. , 0 2 0 0 00 μ / . 0 d 0 0 0 0). / 1 0 φ 0 0 1 1 1 0 fi - _ 0 0 0 ο. 0 - _ | 0 b -1 0 -0 0 1 0 0))) 0 Ó 0 0 0 fi 1 Ī fi 0 1 -10-0 0 0 - 00 -10, υο -10, ο ο , 0 1 0 0 _ -γ 0 0 0 0 ľ I 0 0 0 0 o l -_ 0 0 0 - 0

Authors' contributions

0 ' Ľ' ١ 1. 0 1 .

Conflict of interest

Ο.

Acknowledgements

References

1

0 0 0, , , 1 Ø,)1-0 0 6 - 0 0 0 .1 1 1 1 (01) _ ... 00 0 , 0 _0 . - (1 1). 0 .- 0 , . 0 |,| . 0 0 -(00)6-1-6 .

- 0 6 - 0 (010) 10 -10 . 1 1 J, o, . 0
- , 0 1 0 0 0 00 $O_{i}^{\mu} = O_{i}^{\mu}$ lo oll, h , -! . . . 1 (01) 127. , J. oo. .- 0
- . 0 0 (01) 66 6 66 .
- ... 0,...0,...,..0 (_) 0' 0-0 0,000 0 0 0 0 o fi 0 00, 6 . J. 0. . 0 ,... (01)1 -10.
- 0 0 10 Ο, 0 0 o I 0 0'0 6 (011) 1- . 0 0 .
- 11 J. ol, . . o, . . 110 (06) – . 0 - I 1 0 0
- , . . . o 1 0 0 , 100 - (00)6 L-1
- ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...
 ...</t
- 1 (001)66 & 6. 1

- 0 ... , ... o , ... o , . o ... o ..